Coloplast stock
Price history
−11.18% over the period1 year: from kr 574.00 (November 17, 2025) to kr 509.80 (November 16, 2026), −11.18%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 509.80 |
| October 30, 2026 | kr 482.30 |
| September 30, 2026 | kr 417.90 |
| August 31, 2026 | kr 458.80 |
| July 31, 2026 | kr 429.40 |
| June 30, 2026 | kr 372.30 |
| May 29, 2026 | kr 395.80 |
| April 30, 2026 | kr 393.90 |
| March 31, 2026 | kr 436.40 |
| February 27, 2026 | kr 488.00 |
| January 30, 2026 | kr 536.00 |
| December 30, 2025 | kr 546.40 |
| November 28, 2025 | kr 580.80 |
| November 17, 2025 | kr 574.00 |
At a glance
The company
Develops and sells intimate healthcare products and services, including ostomy, continence, wound and voice and respiratory care
Latest results
Quarter to September 30, 2026 · EPS kr 5.67 (estimate kr 5.82)
TickerLandia's take on Coloplast
- Priced as usual relative to earnings: P/E on the latest fiscal year 37 vs a median of 36 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 37 vs 42 (−11%) in a group of 10.
- Strong point: Dividend (89/100 in its group). Weak point: Financial strength (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−13.76% from the 52-week high
Analysts · 21 analysts
Average targetkr 473.81−7.13% vs. price
Buy 3 · Hold 15 · Sell 3 · Hold
TickerLandia Fingerprint: Coloplast
Compared with similar companies: very high dividend.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage59
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 16.1 49 P/E (trailing 12 months) 37.2 55 Forward P/E 18.8 46 Price/book 8.01 84 Price/sales 3.96 60 Profitabilityhigh74
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 66.5% 81 Net margin 10.6% 63 ROE 20.2% 75 ROA 9.8% 72 Operating margin 25.7% 78 Earnings stabilityhigh66
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 69 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +35.60% 53 Revenue growth (year over year) +7.20% 60 Average revenue growth (3 years) +5.71% 51 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 1.51 8 Current ratio 0.74 4 Interest coverage 11.3 78 Dividendvery high89
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 27 years 71 Dividend yield 4.5% 98 Payout ratiopays out more than its earnings 168.6% 98 Market momentumaverage48
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −15.59% 13 Distance from 200-day average +16.24% 83 Riskhigh71
How much the price swings.
Metric Value Position in group Volatility (60 days) 29.3% 58 Maximum drawdown (12 months) 38.1% 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Coloplast is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), Coloplast's P/E today is 37.4, in line with the median of its last 10 fiscal years (35.7; between 28.6 and 51.0 from 2017 to 2026). Coloplast's P/E (trailing 12 months): 37.2, −11% against the median of a group of 10 similar companies (41.9).
Compared with 10 similar companies
| Metric | Coloplast | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 37.2 | Middle | |
| Forward P/E | 18.8 | Middle | |
| Operating margin | 25.7% | High | |
| ROE | 20.2% | High | |
| Debt/equity | 1.51 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Coloplast. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 7.46B
Latest quarter · Q3 2026
Net income
kr 1.19B
Latest quarter · Q3 2026
Quarterly net margin
15.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 114.49B
- P/E
- 37.2
- EPS
- kr 13.64
- Volume
- 295.52K
- Daily trading
- €28.75M
- Dividend yield
- 0.98%
- Last ex-dividend on May 18, 2026
How Coloplast is changing
All resultsRevenue grew 8.3% a year on average over the last 5 years
Operating margin fell from 28.0% to 25.7%
Profits turn into cash: free cash flow equal to 115% of net income
Returns
Coloplast returns with dividends
kr 1,000 invested in Coloplast 5 years ago, on November 16, 2021, would be worth kr 502 today with dividends reinvested: −49.80% in total, −12.88% per year. On price alone it would be kr 437 (−56.28%).
| Period | Coloplast | kr 1,000 becomes |
|---|---|---|
| 1 month | +7.96% | kr 1,080 |
| 6 months | +27.77% | kr 1,278 |
| Year to date | −6.70% | kr 933 |
| 1 year | −7.30% | kr 927 |
| 3 years | −23.45% | kr 765 |
| 5 years | −49.80% | kr 502 |
| 10 years | +52.28% | kr 1,523 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Coloplast: technical analysis
Coloplast shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 56.9% below its all-time closing high (kr 1,182.50, August 5, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +16.78%
Support and resistance
Price areas where Coloplast has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 587.30+15.11%2 touches, last on January 13, 2026
- Resistancekr 534.20+4.70%3 touches, last on November 5, 2026
- Last pricekr 510.20
- Supportkr 446.70−12.45%4 touches, last on November 3, 2026
- Supportkr 419.56−17.77%8 touches, last on September 24, 2026
- Supportkr 392.37−23.10%3 touches, last on July 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 27.3%
- Largest fall in the last year
- −36.81%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Coloplast: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Coloplast has been July: +3.19% on average, positive in 20 years out of 27. The weakest has been September: −1.04% on average, positive in 13 years out of 27. November, the current month, has been positive in 12 years out of 26 (+0.50% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.96% | +1.88% | 17 of 26 |
| February | +1.95% | +2.33% | 17 of 27 |
| March | +1.36% | +0.84% | 16 of 27 |
| April | +2.92% | +3.13% | 19 of 27 |
| May | −0.99% | +0.48% | 14 of 27 |
| June | −0.96% | −1.92% | 11 of 27 |
| July | +3.19% | +3.20% | 20 of 27 |
| August | +0.98% | 0.00% | 12 of 27 |
| September | −1.04% | −0.10% | 13 of 27 |
| October | +2.61% | +1.53% | 17 of 27 |
| November | +0.50% | 0.00% | 12 of 26 |
| December | +0.13% | −0.30% | 11 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Coloplast and its competitors
SenSura ostomy appliances, Conveen urine bags, SpeediCath catheters, Peristeen irrigation systems, Biatain and Comfeel wound dressings and the Provox voice prosthesis are among the products through which Coloplast sells intimate healthcare products and services. Its range spans ostomy, continence, wound care, urology and voice and respiratory care, sold in Denmark, the United States, the United Kingdom, France and other markets abroad. The company also offers Brava ostomy accessories and Tracoe tracheostomy care products.
- Headquarters
- Humlebæk, Denmark
- Employees
- 17,270
- Founded
- 1954
- Chief executive
- Gavin Wood
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ColoplastCOLO.B | $16.93B | 25.7% | 37.2 | +27.77% |
| SartoriusSRT | $19.89B | 17.8% | 79.3 | +37.44% |
| Straumann HoldingSTMN | $20.69B | 24.7% | 47.1 | +30.05% |
| Sartorius Stedim BiotechDIM | $24B | 19.2% | 67.0 | +44.45% |
| AlconALC | $35.8B | 12.9% | 57.3 | +23.24% |
| Ypsomed HoldingYPSN | $6.77B | 36.2% | 34.3 | +44.57% |
Same industry or related industries, similar size. Compare Coloplast with its competitors · Full profile
